Welcome to our dedicated page for ARS Pharms SEC filings (Ticker: SPRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. ARS Pharma describes itself as a commercial-stage biopharmaceutical company focused on epinephrine nasal spray products for emergency treatment of Type I allergic reactions, including anaphylaxis, and its filings help investors understand how this business is being financed, governed, and developed.
Recent Forms 8-K illustrate several important themes. Some filings report financial results and business updates for specific quarters, where ARS Pharma furnishes press releases discussing revenue from neffy, commercial launch progress, and cash resources. These items fall under “Results of Operations and Financial Condition” and “Regulation FD Disclosure,” and are incorporated by reference to attached exhibits.
Other 8-Ks describe material definitive agreements and financing arrangements, such as the senior secured term loan facility of up to $250 million with affiliates of RA Capital Management and OMERS Life Sciences. These filings outline the structure of the term loans, interest terms, collateral, covenants, and intended use of proceeds, which ARS Pharma states include funding research, development, and commercialization activities for its products, as well as general corporate purposes.
ARS Pharma also uses 8-K filings to disclose legal and intellectual property developments. For example, the company has reported receiving a Paragraph IV certification notice related to a proposed generic version of neffy 2 mg (epinephrine nasal spray) and has stated its intention to pursue patent infringement litigation to defend its listed U.S. patents.
Through Stock Titan, users can track these filings as they are posted to EDGAR and use AI-powered summaries to quickly understand the main points of each document. This includes highlighting where ARS Pharma discusses neffy’s commercialization, financing arrangements, intellectual property strategy, and other material events that may be relevant to shareholders and prospective investors.
ARS Pharmaceuticals filings report beneficial ownership by a Millennium-affiliated group. Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclose shared voting and dispositive power over 5,194,497 and 5,916,030 common shares respectively, shown as 5.2% and 6.0% of the class on the cover pages.
The filing is a joint Schedule 13G/A amendment dated in late March 2026 and includes a Joint Filing Agreement among the four reporting parties. The statement clarifies that the securities are held by entities subject to voting control and investment discretion by Millennium-affiliated managers.
Millennium Management LLC and affiliates reported beneficial ownership of 5,391,440 shares of ARS Pharmaceuticals common stock, representing 5.4%. The filing is a joint Schedule 13G cover dated 03/17/2026 and signed under a Joint Filing Agreement dated 03/23/2026.
The disclosure shows shared voting and shared dispositive power of 5,391,440 shares across Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
ARS Pharmaceuticals, Inc. files its annual report outlining rapid commercialization of neffy, a needle-free intranasal epinephrine spray for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is approved in the U.S., EU, U.K., Japan, Australia and China, with additional reviews pending in Canada.
The company is building a large U.S. and partnered ex‑U.S. sales footprint, targeting high‑volume allergists and pediatricians and using direct‑to‑consumer campaigns and a virtual prescribing platform. Management highlights broad commercial insurance coverage, growing physician adoption, real‑world data showing response rates similar to injections, and a sizeable global market opportunity in both anaphylaxis and chronic urticaria.
ARS Pharmaceuticals, Inc. reported fourth quarter and full-year 2025 results and detailed the commercial rollout of its needle-free epinephrine nasal spray, neffy. For 2025, total revenue was $84.3 million, including $72.2 million in U.S. net product revenue from neffy, $9.7 million in collaboration revenue, and $2.4 million from supply agreements.
Operating expenses rose sharply as the company invested in commercialization, with selling, general and administrative costs of $230.1 million and research and development expenses of $13.2 million, leading to a full-year net loss of $171.3 million, or $1.74 per share. As of December 31, 2025, ARS held $245.0 million in cash, cash equivalents and short-term investments and reported 99,290,926 common shares outstanding.
The company highlighted neffy’s first full year of U.S. sales, progress in securing payer coverage, growing direct-to-consumer marketing, an expanded sales force planned for 2026, and continued global approvals, including in China and Australia. ARS also advanced its intranasal epinephrine program into a Phase 2b trial for chronic spontaneous urticaria, with interim data expected in the second half of 2026.
ARS Pharmaceuticals, Inc. received a new large-shareholder disclosure from Rubric Capital Management LP and David Rosen. They report beneficial ownership of 6,200,000 shares of common stock, representing 6.27% of the company’s outstanding shares, based on 98,848,611 shares outstanding as of November 6, 2025.
The filing shows Rubric Capital and Rosen have shared voting and dispositive power over all 6.2 million shares, with no sole voting or dispositive authority. Rubric Capital Master Fund LP has the right to receive dividends or sale proceeds from more than 5% of the common stock.
The securities are described as acquired and held in the ordinary course of business, and not for the purpose or effect of changing or influencing control of ARS Pharmaceuticals.
BlackRock, Inc. has filed a Schedule 13G reporting beneficial ownership of 5,013,000 shares of ARS Pharmaceuticals, Inc. common stock, representing 5.1% of the class as of 12/31/2025. BlackRock reports sole voting power over 4,929,603 shares and sole dispositive power over 5,013,000 shares, with no shared voting or dispositive power.
The filing explains that these holdings are attributed to specific BlackRock business units and that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares. BlackRock certifies that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of ARS Pharmaceuticals.
ARS Pharmaceuticals (SPRY) chief operating officer reports option exercise and share sale. On 11/13/2025, the officer exercised a stock option for 21,828 shares of common stock at an exercise price of $0.64 per share and then sold 21,828 shares of common stock the same day at a weighted average price of $8.7067 per share. Following these transactions, the officer directly held 10,789 shares of ARS Pharmaceuticals common stock. The reported holdings include shares previously acquired under the company’s 2020 Employee Stock Purchase Plan on December 31, 2024 and June 30, 2025.
ARS Pharmaceuticals, Inc. (SPRY) reported an insider transaction by its Chief Business Officer on a Form 4. On 11/12/2025, the officer exercised a stock option for 30,000 shares of common stock at an exercise price of $0.84 per share and then sold 30,000 shares at a weighted average price of $8.9119. The officer also sold an additional 136,380 shares of common stock at a weighted average price of $8.8634. Following these transactions, the officer reported 0 shares of common stock directly owned and 89,047 stock options beneficially owned.
ARS Pharmaceuticals (SPRY) reported Q3 2025 results with neffy momentum driving higher sales but widening losses. Product revenue, net was $31,300 (in thousands) versus $568 (in thousands) a year ago, lifting total revenue to $32,501 (in thousands) from $2,068 (in thousands).
Spending scaled with launch activity: cost of goods sold was $8,191 (in thousands), R&D $2,751 (in thousands), and SG&A $74,751 (in thousands). The quarter’s net loss was $(51,151) (in thousands), or $(0.52) per share. Cash, cash equivalents, and short‑term investments totaled $288.2 million as of September 30, 2025, supported by new term debt; term loans, net were $96,229 (in thousands) and a financing liability was $72,044 (in thousands).
The company transitioned in August 2025 from a title model to direct sales, recognizing revenue upon delivery and title transfer to wholesalers and pharmacies. Shares outstanding were 98,848,611 as of November 6, 2025.
ARS Pharmaceuticals (SPRY) furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company issued a press release attached as Exhibit 99.1 and updated its investor presentation attached as Exhibit 99.2.
Both exhibits are furnished, not filed, under Items 2.02 and 7.01, meaning they are not subject to Section 18 liability and are not incorporated into other filings except by specific reference. SPRY’s common stock trades on The Nasdaq Stock Market LLC.